Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Charles River Laboratories $875 million acquisition of Cognate
We advised Charles River on the acquisition of a cell and gene therapy contract development and manufacturing organization
Corvus Pharmaceuticals $34 million stock offering
We advised the underwriters on the equity offering
Biogen exchange offer
We advised the dealer managers on a debt exchange offer
Oak Street Health $600.5 million secondary offering
We advised the joint book-running managers on the equity offering
Signify Health $648.6 million IPO
We advised Signify Health on its IPO and NYSE listing
Adagene $161 million IPO
We advised Adagene on its IPO and Nasdaq listing
Cornell Capital acquires trustaff and CardioSolution in combination with Stella
We are advising Cornell Capital on the acquisition
Bolt Biotherapeutics $230 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Immunocore $297 million IPO
We advised the joint book-running managers and underwriters on the IPO and Nasdaq listing
Terns Pharmaceuticals $127.5 million IPO
We advised the underwriters on the IPO and Nasdaq listing